Trials / Conditions / Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

24 registered clinical trials studyying Giant Cell Arteritis (GCA) — 20 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeuti NCT07269938	University of Edinburgh	—
Not Yet Recruiting	Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement. NCT07354906	Groupe français d'étude des Maladies Inflammatoires de loeil	—
Recruiting	The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis NCT07246577	Vastra Gotaland Region	—
Not Yet Recruiting	Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rhe NCT07394478	Hôpital NOVO	—
Not Yet Recruiting	Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone NCT06833411	Insel Gruppe AG, University Hospital Bern	Phase 3
Recruiting	Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis NCT07108387	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Not Yet Recruiting	Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis NCT07206238	Rigshospitalet, Denmark	—
Recruiting	oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound NCT07001059	Hôpital NOVO	N/A
Not Yet Recruiting	Bosentan in the Treatment of Giant Cell Arteritis NCT06957002	Assistance Publique - Hôpitaux de Paris	Phase 2
Not Yet Recruiting	Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients NCT07060274	Centre Hospitalier le Mans	N/A
Recruiting	Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy NCT07150000	University of Bonn	—
Recruiting	Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) NCT06887062	University of Edinburgh	Phase 2
Recruiting	Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis NCT06742671	Groupe Hospitalier de la Rochelle Ré Aunis	—
Not Yet Recruiting	A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic NCT06766552	Second Affiliated Hospital, School of Medicine, Zhejiang University	—
Enrolling By Invitation	Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases NCT06763783	Region Skane	Phase 4
Recruiting	AYLo - AutoimmunitY and Loss of y NCT06696027	University of Bonn	—
Recruiting	Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) P NCT06609668	Centre Hospitalier Universitaire Dijon	—
Recruiting	TocILizumab in aorTitis in GCA (TILT) NCT06271018	Groupe français d'étude des Maladies Inflammatoires de loeil	—
Completed	Cardiac Involvement in Patients With Giant Cell Arteritis NCT07031284	University Hospital, Bonn	—
Recruiting	Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Ce NCT05479448	University Hospital, Basel, Switzerland	—
Recruiting	Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoi NCT05193396	Marianne Andersen	Phase 4
Completed	Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper NCT04930094	Novartis Pharmaceuticals	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis NCT03725202	AbbVie	Phase 3
Completed	TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Pa NCT07459335	Groupe français d'étude des Maladies Inflammatoires de loeil	—